Source comparison
How to Use Hexarelin for Cardiac Protection Protocol: Comparison
Dose per administration 200–300 mcg 100–150 mcg Lower dose targets CD36 receptor activation without saturating GH-axis pathways Frequency 2–3× daily (morning, post-training, pre-sleep) 1× daily, pre-stress timing Single daily dose maintains receptor occupancy
This comparison does not assign a generated winner or score.
- Dose per administration
- 200–300 mcg
- 100–150 mcg
- Lower dose targets CD36 receptor activation without saturating GH-axis pathways
- Frequency
- 2–3× daily (morning, post-training, pre-sleep)
- 1× daily, pre-stress timing
- Single daily dose maintains receptor occupancy for cardioprotection without desensitisation
- Primary mechanism
- Pituitary GH release → IGF-1 elevation
- Direct CD36 scavenger receptor binding in myocardial tissue
- Cardioprotection persists even when GH release is pharmacologically blocked
- Cycle structure
- 5 days on / 2 days off, continuous
- 4 weeks on / 2 weeks off
- Off-cycle periods restore CD36 receptor density and preserve long-term efficacy
- Stacking compounds
- Other GHRPs (ipamorelin, GHRP-2) for synergistic GH peaks
- Avoid GHRP stacking; consider taurine, CoQ10 for complementary pathways
- GHRP stacking dilutes CD36 signalling. Cardioprotection is a monotherapy application
- Measurable outcomes
- Lean mass gain, recovery speed, sleep quality
- HRV improvement, reduced hs-CRP, faster post-exertion HR recovery
- Biomarker tracking (HRV, hs-CRP) confirms therapeutic effect within 2–3 weeks